• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在意大利,接受过口服 HIV 预防药物(PrEP)的男男性行为者队列中,卡替拉韦长效注射制剂具有较高的转换意愿。

High Propensity to Switch to Long-acting Injectable HIV PrEP with Cabotegravir in a Cohort of Oral PrEP Experienced Men who Have Sex with Men in Italy.

机构信息

Vita-Salute San Raffaele University, Via Stamira D'Ancona 20, Milano, 20127, Italy.

Infectious Diseases Unit, San Raffaele Scientific Institute, Milan, Italy.

出版信息

AIDS Behav. 2024 Mar;28(3):907-911. doi: 10.1007/s10461-023-04197-8. Epub 2023 Oct 4.

DOI:10.1007/s10461-023-04197-8
PMID:37792228
Abstract

Aim was to investigate the propensity to switch to long-acting injectable HIV pre-exposure prophylaxis (PrEP) with cabotegravir among oral PrEP-experienced men who have sex with men. Out of 377 PrEP users, 325 (86.2%) were interested (would like = 210) or considering (would consider = 115) switch to long-acting PrEP. At multivariable analysis, the odds ratio of interest in long-acting PrEP in non-adherent vs. adherent individuals to oral PrEP was 5.03 (95%CI = 1.73-14.61,p = 0.003) and of consideration 1.63 (95%CI = 0.51-5.23,p = 0.410). We observed very high propensity to switch to long-acting PrEP, particularly among non-adherent users. Rapid availability of long-acting PrEP might address unmet needs of PrEP users in Italy.

摘要

目的在于调查有过口服暴露前预防(PrEP)用药史的男男性行为者(MSM)对改用长效注射型 HIV 暴露前预防(PrEP)药物卡替拉韦的倾向。在 377 名 PrEP 用户中,325 名(86.2%)表示有兴趣(愿意=210 人)或考虑(会考虑=115 人)改用长效 PrEP。多变量分析显示,与口服 PrEP 依从性个体相比,不依从性个体对长效 PrEP 的兴趣的优势比为 5.03(95%CI=1.73-14.61,p=0.003),考虑的优势比为 1.63(95%CI=0.51-5.23,p=0.410)。我们观察到改用长效 PrEP 的意愿非常高,尤其是在不依从性使用者中。长效 PrEP 的快速供应可能会满足意大利 PrEP 用户的未满足需求。

相似文献

1
High Propensity to Switch to Long-acting Injectable HIV PrEP with Cabotegravir in a Cohort of Oral PrEP Experienced Men who Have Sex with Men in Italy.在意大利,接受过口服 HIV 预防药物(PrEP)的男男性行为者队列中,卡替拉韦长效注射制剂具有较高的转换意愿。
AIDS Behav. 2024 Mar;28(3):907-911. doi: 10.1007/s10461-023-04197-8. Epub 2023 Oct 4.
2
Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States.在美国,卡博特韦长效制剂用于HIV暴露前预防的成本效益分析
Pharmacoeconomics. 2024 Apr;42(4):447-461. doi: 10.1007/s40273-023-01342-y. Epub 2024 Jan 24.
3
Cabotegravir Extended-Release Injectable Suspension: A Review in HIV-1 Pre-Exposure Prophylaxis.卡博特韦长效注射混悬剂:用于 HIV-1 暴露前预防的综述。
Drugs. 2022 Sep;82(14):1489-1498. doi: 10.1007/s40265-022-01791-3. Epub 2022 Oct 18.
4
High Interest in Long-acting Injectable Pre-exposure Prophylaxis (LAI-PrEP) for HIV Prevention Among Men Who Have Sex With Men (MSM): Result From A Nationwide Survey in Malaysia.男男性行为者(MSM)对长效注射型 HIV 预防用药(LAI-PrEP)的高度关注:来自马来西亚全国性调查的结果。
J Community Health. 2023 Jun;48(3):513-521. doi: 10.1007/s10900-023-01195-8. Epub 2023 Feb 3.
5
Willingness and preferences for long-acting injectable PrEP among US men who have sex with men: a discrete choice experiment.美国男男性行为者对长效注射用暴露前预防药物的意愿和偏好:一项离散选择实验
BMJ Open. 2024 Apr 22;14(4):e083837. doi: 10.1136/bmjopen-2023-083837.
6
Preferences for long-acting pre-exposure prophylaxis among gay, bisexual and other men who have sex with men in Taiwan: findings from the 2021 HEART Survey.台湾地区男同性恋、双性恋和其他男男性行为者对长效暴露前预防的偏好:来自 2021 年“心脏”调查的结果。
J Int AIDS Soc. 2023 Sep;26(9):e26163. doi: 10.1002/jia2.26163.
7
Changing from Tenofovir/Emtricitabine to Cabotegravir for Pre Exposure Prophylaxis for HIV in Men who have Sex with Men: A Cost Utility Analysis from an Endemic Country.从替诺福韦/恩曲他滨转换为卡博特韦用于男男性行为者的HIV暴露前预防:来自一个流行国家的成本效用分析
J Assoc Physicians India. 2022 Feb;70(2):11-12.
8
Systematic review of the values and preferences regarding the use of injectable pre-exposure prophylaxis to prevent HIV acquisition.系统评价关于使用注射用暴露前预防措施预防 HIV 感染的价值观和偏好。
J Int AIDS Soc. 2023 Jul;26 Suppl 2(Suppl 2):e26107. doi: 10.1002/jia2.26107.
9
Willingness to take long-acting injectable pre-exposure prophylaxis among men who have sex with men who participated in the CROPrEP study: a cross-sectional online study.在参与 CROPrEP 研究的男男性行为者中,使用长效注射型暴露前预防的意愿:一项横断面在线研究。
BMC Public Health. 2023 Dec 13;23(1):2494. doi: 10.1186/s12889-023-17325-9.
10
Injectable Pre-Exposure Prophylaxis for HIV Prevention: Perspectives on the Benefits and Barriers from Gay, Bisexual, and Queer Men and Health System Stakeholders in Ontario, Canada.注射用 HIV 预防暴露前预防:安大略省男同性恋、双性恋和酷儿人群及卫生系统利益相关者对其益处和障碍的看法。
AIDS Patient Care STDS. 2023 Jun;37(6):306-315. doi: 10.1089/apc.2023.0034. Epub 2023 May 16.

引用本文的文献

1
Control of HIV across the WHO European region: progress and remaining challenges.世卫组织欧洲区域的艾滋病毒防控:进展与尚存挑战
Lancet Reg Health Eur. 2025 Feb 20;52:101243. doi: 10.1016/j.lanepe.2025.101243. eCollection 2025 May.
2
Unconventional use of injectable long-acting cabotegravir and rilpivirine against HIV-1 in PWH in clinical need: 52 weeks real-world data.针对有临床需求的艾滋病毒感染者非常规使用注射用长效卡博特韦和利匹韦林抗HIV-1:52周真实世界数据
BMC Infect Dis. 2025 Jan 22;25(1):105. doi: 10.1186/s12879-025-10499-0.

本文引用的文献

1
Exploring preferences and decision-making about long-acting injectable HIV pre-exposure prophylaxis (PrEP) among young sexual minority men 17-24 years old.探讨 17-24 岁年轻性少数男性对长效注射型 HIV 暴露前预防(PrEP)的偏好和决策。
Sci Rep. 2023 Mar 29;13(1):5116. doi: 10.1038/s41598-023-32014-8.
2
Willingness to use and preferences for long-acting injectable PrEP among sexual and gender minority populations in the southern United States, 2021-2022: cross-sectional study.2021-2022 年美国南部性少数群体和性别少数群体对长效注射型 PrEP 的使用意愿和偏好:横断面研究。
J Int AIDS Soc. 2023 Mar;26(3):e26077. doi: 10.1002/jia2.26077.
3
Preferences for PrEP modalities among gay, bisexual, and other men who have sex with men from Brazil, Mexico, and Peru: a cross-sectional study.
巴西、墨西哥和秘鲁的男同性恋、双性恋及其他与男性发生性行为的男性对暴露前预防方式的偏好:一项横断面研究。
Ther Adv Infect Dis. 2023 Feb 18;10:20499361231153548. doi: 10.1177/20499361231153548. eCollection 2023 Jan-Dec.
4
Safety and efficacy of long-acting injectable cabotegravir as preexposure prophylaxis to prevent HIV acquisition.长效注射用卡替拉韦作为暴露前预防措施预防 HIV 感染的安全性和有效性。
AIDS. 2023 May 1;37(6):957-966. doi: 10.1097/QAD.0000000000003494. Epub 2023 Jan 25.
5
The propensity for long-acting cabotegravir and rilpivirine every 2 months among HIV-infected people eligible for treatment.符合治疗条件的HIV感染者每两个月使用长效卡博特韦和rilpivirine的倾向。
J Med Virol. 2023 Jan;95(1):e28330. doi: 10.1002/jmv.28330.
6
Examining the Awareness, Acceptability, and Adoption of Conventional and non-conventional Forms of Pre-Exposure Prophylaxis (PrEP) for HIV Prevention Among jail-involved Black Sexual Minority men (BSMM) and Black Transgender Women (BTW) in Two Diverse US Cities.调查监狱内涉及的美国两个不同城市中的黑人男同性恋者(BSMM)和黑人跨性别女性(BTW)对 HIV 预防的常规和非传统形式的暴露前预防(PrEP)的认知、可接受性和采用情况。
AIDS Behav. 2023 Apr;27(4):1304-1313. doi: 10.1007/s10461-022-03866-4. Epub 2022 Oct 20.
7
Zero knowledge and high interest in the use of long-acting injectable pre-exposure prophylaxis (PrEP) among adolescent men who have sex with men and transgender women in two capital cities in Brazil.在巴西两个首府城市,男男性行为者和跨性别女性对使用长效注射型暴露前预防(PrEP)的零知识和高度兴趣。
BMC Public Health. 2022 Sep 12;22(1):1728. doi: 10.1186/s12889-022-14134-4.
8
Acceptability of multiple modalities of pre-exposure prophylaxis (PrEP) among female sex workers in Tanzania: a mixed-methods study.坦桑尼亚女性性工作者对多种暴露前预防(PrEP)措施的可接受性:一项混合方法研究。
BMJ Open. 2022 Aug 17;12(8):e058611. doi: 10.1136/bmjopen-2021-058611.
9
Daily and on-demand HIV pre-exposure prophylaxis with emtricitabine and tenofovir disoproxil (ANRS PREVENIR): a prospective observational cohort study.每日按需服用恩曲他滨和替诺福韦地索普西(ANRS PREVENIR)进行艾滋病毒暴露前预防:一项前瞻性观察队列研究。
Lancet HIV. 2022 Aug;9(8):e554-e562. doi: 10.1016/S2352-3018(22)00133-3. Epub 2022 Jun 27.
10
Real-world effectiveness of pre-exposure prophylaxis in men at high risk of HIV infection in France: a nested case-control study.法国高危感染 HIV 男性人群中,暴露前预防的真实世界有效性:一项巢式病例对照研究。
Lancet Public Health. 2022 Jun;7(6):e529-e536. doi: 10.1016/S2468-2667(22)00106-2.